Evidence map›Paper›PMID 30058798›Full record

ArticleACS infectious diseases2018

High Throughput Screen Identifies Interferon γ-Dependent Inhibitors of Toxoplasma gondii Growth.

Joshua B Radke, Kimberly L Carey, Subrata Shaw, Shailesh R Metkar, Carol Mulrooney, Jennifer P Gale, Joshua A Bittker, Robert Hilgraf, Eamon Comer, Stuart L Schreiber and 3 more

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Susceptibility ofmBio · 2024
    Article
  2. Review
  3. Modulation of autophagy as a therapeutic strategy forFrontiers in cellular and infection microbiology · 2022
    Review
  4. Review
  5. A NovelFrontiers in microbiology · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Joshua B RadkeDepartment of Molecular Microbiology , Washington University in Saint Louis School of Medicine , 660 S. Euclid Avenue , St. Louis , Missouri 63110 , United States.
Kimberly L CareyInfectious Disease and Microbiome Program , Broad Institute , Cambridge , Massachusetts 02142 , United States.
Subrata ShawCenter for the Development of Therapeutics , Broad Institute of MIT and Harvard , 415 Main Street , Cambridge , Massachusetts 02142 , United States.
Shailesh R MetkarCenter for the Development of Therapeutics , Broad Institute of MIT and Harvard , 415 Main Street , Cambridge , Massachusetts 02142 , United States.
Carol MulrooneyCenter for the Development of Therapeutics , Broad Institute of MIT and Harvard , 415 Main Street , Cambridge , Massachusetts 02142 , United States.
Jennifer P GaleCenter for the Development of Therapeutics , Broad Institute of MIT and Harvard , 415 Main Street , Cambridge , Massachusetts 02142 , United States.
Joshua A BittkerCenter for the Development of Therapeutics , Broad Institute of MIT and Harvard , 415 Main Street , Cambridge , Massachusetts 02142 , United States.
Robert HilgrafCenter for the Development of Therapeutics , Broad Institute of MIT and Harvard , 415 Main Street , Cambridge , Massachusetts 02142 , United States.
Eamon ComerChemical Biology and Therapeutics Science Program , Broad Institute , Cambridge , Massachusetts 02142 , United States.
Stuart L SchreiberChemical Biology and Therapeutics Science Program , Broad Institute , Cambridge , Massachusetts 02142 , United States.
Herbert W VirginDepartment of Pathology and Immunology , Washington University in Saint Louis School of Medicine , 660 S. Euclid Avenue , St. Louis , Missouri 63110 , United States.
Jose R PerezCenter for the Development of Therapeutics , Broad Institute of MIT and Harvard , 415 Main Street , Cambridge , Massachusetts 02142 , United States.
L David SibleyDepartment of Molecular Microbiology , Washington University in Saint Louis School of Medicine , 660 S. Euclid Avenue , St. Louis , Missouri 63110 , United States.ORCID 0000-0001-7110-0285
Broad Institute · USWashington University in St. Louis · US

Funding

Genetic and Pathway Analysis CoreU19AI109725 · NIAID · WASHINGTON UNIVERSITY · PI VIRGIN, HERBERT W · 2014 to 2018
$32.7M
Molecular Basis of Human ToxoplasmosisR01AI118426 · NIAID · WASHINGTON UNIVERSITY · PI SIBLEY, L. DAVID · 2015 to 2024
$6.0M
NIAID NIH HHS R01 AI118426NIAID NIH HHS U19 AI109725
6 · The paper itself

Abstract

Toxoplasma gondii is an obligate intracellular parasite capable of causing severe disease due to congenital infection and in patients with compromised immune systems. Control of infection is dependent on a robust Th1 type immune response including production of interferon gamma (IFN-γ), which is essential for control. IFN-γ activates a variety of antimicrobial mechanisms in host cells, which are then able to control intracellular parasites such as T. gondii. Despite the effectiveness of these pathways in controlling acute infection, the immune system is unable to eradicate chronic infections that can persist for life. Similarly, while antibiotic treatment can control acute infection, it is unable to eliminate chronic infection. To identify compounds that would act synergistically with IFN-γ, we performed a high-throughput screen of diverse small molecule libraries to identify inhibitors of T. gondii. We identified a number of compounds that inhibited parasite growth in vitro at low μM concentrations and that demonstrated enhanced potency in the presence of a low level of IFN-γ. A subset of these compounds act by enhancing the recruitment of light chain 3 (LC3) to the parasite-containing vacuole, suggesting they work by an autophagy-related process, while others were independent of this pathway. The pattern of IFN-γ dependence was shared among the majority of analogs from 6 priority scaffolds, and analysis of structure activity relationships for one such class revealed specific stereochemistry associated with this feature. Identification of these IFN-γ-dependent leads may lead to development of improved therapeutics due to their synergistic interactions with immune responses.

Indexed as

AutophagyGreen Fluorescent ProteinsGrowth InhibitorsHeLa CellsHigh-Throughput Screening AssaysHumansImmunity, InnateInterferon-gammaLinear ModelsLuciferasesMicrotubule-Associated ProteinsProtein BindingSmall Molecule LibrariesStereoisomerismTh1 CellsToxoplasmaGreen Fluorescent ProteinsGrowth InhibitorsInterferon-gammaLuciferasesMAP1LC3A protein, humanMicrotubule-Associated ProteinsSmall Molecule Librariesantibioticsautophagybroad spectrumdiversity-oriented synthesisinnate immunityinterferonintracellular parasitesmall molecule inhibitorstoxoplasmosis

Identifiers

PMID30058798
PMCPMC6200635
OpenAlexW2805899966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.